Abstract
The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the worlds population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.
Keywords: Molecular Mechanisms, Antibiotic Resistance, Helicobacter pylori, bacterial infections, gastric pathogen, carcinogen, gastric adenocarcinoma, mucosa-associated lymphoid tissue (MALT)
Current Drug Therapy
Title: Whos Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori
Volume: 3 Issue: 3
Author(s): Kathleen R. Jones, Jeong-Heon Cha and D. Scott Merrell
Affiliation:
Keywords: Molecular Mechanisms, Antibiotic Resistance, Helicobacter pylori, bacterial infections, gastric pathogen, carcinogen, gastric adenocarcinoma, mucosa-associated lymphoid tissue (MALT)
Abstract: The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the worlds population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.
Export Options
About this article
Cite this article as:
Jones R. Kathleen, Cha Jeong-Heon and Merrell Scott D., Whos Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori, Current Drug Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157488508785747899
DOI https://dx.doi.org/10.2174/157488508785747899 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beneficial Effects of Bioactive Phospholipids: Genomic Bases
Current Nutrition & Food Science Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Endogenous Modulators of TRP Channels
Current Topics in Medicinal Chemistry Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry Inflammatory Cytokines Pathways as Potential Therapeutic Targets for Gastric Cancer
Current Cancer Therapy Reviews When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets Adenoviral Vectors for Cancer Gene Therapy
Current Genomics Andrographolide Inhibits Osteopontin Expression and Breast Tumor Growth Through Down Regulation of PI3 Kinase/Akt Signaling Pathway
Current Molecular Medicine The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism
Mini-Reviews in Medicinal Chemistry Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry Chitosan and its Derivatives as Chemical Drug Delivery Carriers
Current Organic Chemistry Bioactivity of Sesquiterpenes: Compounds that Protect from Alcohol-Induced Gastric Mucosal Lesions and Oxidative Damage
Mini-Reviews in Medicinal Chemistry Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
Current Cancer Drug Targets C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design The Prognostic Value of Long Non-Coding RNA <i>SNHG7</i> in Human Cancer: A Meta-Analysis
Current Pharmaceutical Biotechnology Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Ca2+ Signalling in Damaged Endothelium: Do Connexin Hemichannels Aid in Filling the Gap?
Current Drug Therapy Exploring Cytotoxic and Atioxidant Properties of <i>Heliotropium calcareum</i> in Polar and Non-Polar Extracts
Current Nutraceuticals